These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 32010873)

  • 1. Metabolomic Analysis of the Effects of Leptin Replacement Therapy in Patients with Lipodystrophy.
    Grewal S; Gubbi S; Fosam A; Sedmak C; Sikder S; Talluru H; Brown RJ; Muniyappa R
    J Endocr Soc; 2020 Jan; 4(1):bvz022. PubMed ID: 32010873
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
    J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New advances in the treatment of generalized lipodystrophy: role of metreleptin.
    Rodriguez AJ; Mastronardi CA; Paz-Filho GJ
    Ther Clin Risk Manag; 2015; 11():1391-400. PubMed ID: 26396524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide.
    Akinci B; Meral R; Rus D; Hench R; Neidert AH; DiPaola F; Westerhoff M; Taylor SI; Oral EA
    Endocrinol Diabetes Metab Case Rep; 2020 Mar; 2020():. PubMed ID: 32213649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.
    Muniyappa R; Brown RJ; Mari A; Joseph J; Warren MA; Cochran EK; Skarulis MC; Gorden P
    Diabetes Care; 2014 Apr; 37(4):1101-7. PubMed ID: 24496806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.
    Brown RJ; Valencia A; Startzell M; Cochran E; Walter PJ; Garraffo HM; Cai H; Gharib AM; Ouwerkerk R; Courville AB; Bernstein S; Brychta RJ; Chen KY; Walter M; Auh S; Gorden P
    J Clin Invest; 2018 Aug; 128(8):3504-3516. PubMed ID: 29723161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy.
    Nagayama A; Ashida K; Watanabe M; Moritaka K; Sonezaki A; Kitajima Y; Takahashi H; Yoshinobu S; Iwata S; Yasuda J; Hasuzawa N; Ozono S; Motomura S; Nomura M
    Front Endocrinol (Lausanne); 2021; 12():690996. PubMed ID: 34135866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptin replacement therapy does not improve the abnormal lipid kinetics of hypoleptinemic patients with HIV-associated lipodystrophy syndrome.
    Sekhar RV; Jahoor F; Iyer D; Guthikonda A; Paranilam J; Elhaj F; Coraza I; Balasubramanyam A
    Metabolism; 2012 Oct; 61(10):1395-403. PubMed ID: 22542724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
    Christensen JD; Lungu AO; Cochran E; Collins MT; Gafni RI; Reynolds JC; Rother KI; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1493-500. PubMed ID: 25070319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
    Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
    J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leptin-Mediated Changes in the Human Metabolome.
    Lawler K; Huang-Doran I; Sonoyama T; Collet TH; Keogh JM; Henning E; O'Rahilly S; Bottolo L; Farooqi IS
    J Clin Endocrinol Metab; 2020 Aug; 105(8):2541-52. PubMed ID: 32392278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
    Muniyappa R; Abel BS; Asthana A; Walter MF; Cochran EK; Remaley AT; Skarulis MC; Gorden P; Brown RJ
    J Clin Lipidol; 2017; 11(2):543-550. PubMed ID: 28502512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
    Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endogenous Leptin Concentrations Poorly Predict Metreleptin Response in Patients With Partial Lipodystrophy.
    Meral R; Malandrino N; Walter M; Neidert AH; Muniyappa R; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2022 Mar; 107(4):e1739-e1751. PubMed ID: 34677608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
    Grover A; Quaye E; Brychta RJ; Christensen J; Startzell MS; Meehan CA; Valencia A; Marshall B; Chen KY; Brown RJ
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4163-e4178. PubMed ID: 33890058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale for leptin-replacement therapy for severe lipodystrophy.
    Oral EA; Chan JL
    Endocr Pract; 2010; 16(2):324-33. PubMed ID: 20061299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on Therapeutic Options in Lipodystrophy.
    Akinci B; Meral R; Oral EA
    Curr Diab Rep; 2018 Oct; 18(12):139. PubMed ID: 30370487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.